Detailed Narrative
Q4 FY25 Financial Performance
Concentra reported Q4 FY25 revenue of $539.1 million, a 15.9% year-over-year increase, and adjusted EBITDA of $95.3 million, up 22.9% year-over-year. For the full year 2025, revenue reached $2.2 billion, up 13.9%, and adjusted EBITDA was $431.9 million, up 14.6%, both exceeding the high end of previous guidance. Adjusted EBITDA margin improved by 100 basis points to 17.7% in Q4 and to 20% for the full year, despite incremental separation and public company costs.
Operational Highlights and Market Dynamics
Total patient visits increased 9% in Q4 FY25, with workers' compensation visits up 9.1% and employer service visits up 9.4%. Excluding acquisitions, total visits per day increased 2.6%. Revenue per visit grew 3.1% in Q4, driven by a 4.1% increase in workers' compensation and 1.2% in employer services. The company noted that the blue-collar economy, representing 80% of their labor force, grew at 0.4% in 2025, adding over 450,000 jobs, providing a tailwind for their business.
Strategic Growth Initiatives
Concentra opened 7 de novo sites in 2025 and plans for 7 to 9 in 2026, with potential for double-digit new sites in 2027, noting these are highly accretive with under 3-year payback periods. The company will continue small bolt-on acquisitions, having recently finalized the Reliant acquisition in January. They are also evaluating inorganic growth opportunities for their Onsite health clinic segment, particularly for advanced primary care product offerings, which have gained traction.
Separation from Select Medical Progress
The company is tracking well on its separation from Select Medical, having hired over 80% of expected full-time employees, including all senior roles. They expect to finalize hiring and most remaining separation activities by summer 2026, well ahead of the November 2026 transition services agreement expiration. This transition is expected to incur some incremental costs in the first half of 2026, but these are factored into the full-year guidance.
New York Market Opportunity Evaluation
Concentra is actively engaging in the public comment period for New York's revised workers' compensation fee schedule. While initial revisions increased evaluation and management codes by approximately 50%, the company believes further adjustments are needed for physical therapy and other codes to make capital commitment meaningful. They are prepared to move quickly with de novo projects or potential acquisitions if rates become favorable, with new rates expected by January 1, 2027.
Cash Flow and Capital Allocation
The company generated $118.7 million in operating cash flow in Q4 FY25 and $279.4 million for the full year. Free cash flow totaled $98.6 million in Q4 and $197.8 million for the full year, with a conversion rate of 114%. They repaid $35 million on their credit facility, repurchased $22.4 million in shares, and paid $8 million in dividends in Q4. The net leverage ratio was 3.4x at year-end, with a target of approximately 3x by year-end 2026.